Previous 10 | Next 10 |
The week was once again eventful in cryptocurrencies, but unlike last week it wasn't dominated by regulatory and political fights . A big announcement came from Coinbase (NASDAQ: COIN) , which built its own Layer 2 blockchain on Ethereum . There's no token for the blockchain,...
Benchmark has upgraded NeoGenomics ( NASDAQ: NEO ) to buy from hold noting that a management performance improvement program is poised to deliver profitability. The firm left its price target unchanged at $20 (20% upside based on Friday's close). Analyst Bruce Jackson said that th...
NeoGenomics, Inc. (NEO) Q4 2022 Earnings Conference Call February 23, 2023, 08:30 AM ET Company Participants Chris Smith - Chief Executive Officer Jeff Sherman - Chief Financial Officer Warren Stone - President of Clinical Service Division Vishal Sikri - President ...
Shares of NeoGenomics (NASDAQ: NEO) were up 23.52% Thursday afternoon after the company released its full-year and fourth-quarter report. The company, which focuses on oncology testing, has seen its shares rise more than 79% so far this year. The healthcare company operates under ...
The following slide deck was published by NeoGenomics, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: NeoGenomics, Inc. 2022 Q4 - Results - Earnings Call Presentation
NeoGenomics ( NASDAQ: NEO ) stock rose ~22% on Thursday after Q4 results beat estimates. Adjusted diluted EPS was -$0.06, compared -$0.14 in Q4 2021, surpassing estimates. Total net revenue grew +10% Y/Y to $138.71M. Clinical Services revenue increased +4% Y/Y to $108.17M,...
NeoGenomics press release ( NASDAQ: NEO ): Q4 Non-GAAP EPS of -$0.06 beats by $0.10 . Revenue of $139M (+10.6% Y/Y) beats by $9.03M . 2023 Guidance: Adjusted EPS $(0.38) - $(0.32) vs. consensus of -$0.53, Adjusted EBITDA $(27) - $(22)M. For further det...
Fourth Quarter Revenue Increased 10% to $139 million; Full Year Revenue Increased 5% to $510 million FORT MYERS, FL / ACCESSWIRE / February 23, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company") , a leading provider of oncology testing and global contract research services, today ann...
NeoGenomics ( NASDAQ: NEO ) is scheduled to announce Q4 earnings results on Thursday, February 23rd, before market open. The consensus EPS Estimate is -$0.16 (-14.3% Y/Y) and the consensus Revenue Estimate is $129.97M (+3.4% Y/Y). Over the last 2 years, NEO has beaten E...
SAN DIEGO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announced that a lawsuit is pending for certain investors in shares of NeoGenomics, Inc. (NASDAQ: NEO). Investors who purchased NeoGenomics, Inc. (NASDAQ: NEO) shares prior to February 27, 2020, and continue to hol...
News, Short Squeeze, Breakout and More Instantly...
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its second quarter 2024 financial results after the close of the U.S. financial markets on Monday, July 29, 2024. Company management will host a webcast and conference call at 4:30 ...
2024-06-23 10:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that Fort Myers’ Mayor, Kevin Anderson, will be dedicating June as NeoGenomics’ Commitment to Cancer Month to honor cancer survivors and those currently living with cancer. Headquartered in...